Article Correctness Is Author's Responsibility: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Results from a phase 2 clinical trial, presented by Seattle Children’s Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-vers…

read more

Article Correctness Is Author's Responsibility: Seattle Children’s Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia that Targets CD22 and CD19 Proteins Simultaneously

Seattle Children’s has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously…

read more